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Vaccine ID Target 
indication
Delivery
system
Notes about 
delivery system
Antigen Antigen function Mass 
(kDa)
Development
phase
Outcomes
MVA85A/
AERAS-485
Preventive -
Preexposure
Modified
Vaccinia Virus 
Ankara (MVA)
Replication-
deficient viral 
delivery system
Ag85A 
(Rv3804c)
Mycolyl transferase
surface protein 
(virulence factor)
35.7 Phase I Safety ✓
Immunogenicity ✓
Efficacy ✗
Ad5Ag85A Preventive -
Preexposure
Recombinant
adenovirus 
serotype 5 
(Ad5)
Replication-
deficient viral 
delivery system
Ag85A 
(Rv3804c)
Mycolyl transferase
surface protein 
(virulence factor)
35.7 Phase IIb Safety ✓
Immunogenicity ✓
Efficacy ✗
AERAS-402 Preventive -
Preexposure
Recombinant
adenovirus 
serotype 35 
(Ad35)
Replication-
deficient viral 
delivery system
Ag85A 
(Rv3804c)
Mycolyl transferase
surface protein
(virulence factor)
35.7 Phase IIb Safety ✓
Immunogenicity ✓
Efficacy ✗
Ag85B 
(Rv1886c)
Fibronectin binding 
protein surface protein
34.6
TB10.4 
(Rv0288)
ESAT-6 family protein 10.4
1882
Discovery of Mtb by
Robert Koch
1890
Development of 
tuberculine by
Robert Koch
1921
Development of BCG 
by Calmette and 
Guérin
1990
Inclusion of BCG in the
Expanded Program on 
Immunization 
1993
Inclusion of TB as 
Global Emergency by
The WHO
2015
16 TB vaccine
candidates in 
pipeline
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Beyond BCG: boosting strategies with viral vector vaccines
Mycobacterium tuberculosis (Mtb) is the causative agent for
tuberculosis disease (TB). In 2013 9M people (1,1 HIV+) developed TB
and 1,5M (360 000 HIV+) died from it. There were also registered 480
000 MDR-TB cases, three times higher than in 1990. HIV-TB
coinfection and the increase of drug resistances have become a
concern towards controlling the disease.
However, it's not all bad news. From 1990 to 2013 the mortality rate
and prevalence have decreased a 45 and 41% respectively, and 37M
lives were saved from 2000 to 2013 due to prevention programms and
TB treatment.
Introduction
The immune response required against Mtb is cell-mediated with T lymphocytes and mononuclear phagocytes (MP). The T-cell response is biased to the Th1
pole. The CD4+ and CD8+ T-cells both secrete INF-γ and TNF-α, that will activate the MP, whereas CD8+ also produce perforins, granulysins and granzyms that
will harm the bacilli. The Th17 response is involved in the early defense and adaptive immunity against TB, it also may be a Th1 recruiter and therefore help
accelerate the bacterial clearance. However, if maintained for long periods can induce pathology due to inflammation. The induction of long-lived memory T-
cells is paramount in terms of control of the bacilli, this may be the major problem in the production of a TB vaccine.
Immune response to Mtb
 In order to control and eventually eradicate TB there is a
need for better diagnostics, treatments and an
efficacious vaccine.
 In every trial conducted to date MVA85A, AdAg85a and
Ad35/AERAS 402 have proved to be safe and
immunogenic, but not efficacious.
 Concerns on adenoviral vectors regarding the potency
for dampening the immune response due to the
induction of neutralizing antibodies have been overcome
 Further investigation is required.
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Vaccination
The Bacille Calmette-Guérin (BCG) is the only vaccine available for
preventing TB. The countries with the highest TB burden have a BCG
vaccination policy. BCG only confers partial protection in children.
Thus, in order to maximize the protection range a secondary boost is
needed.
Viral vector vaccines as boosters of
BCG immunization are an attractive
approach. Replication-deficient
variants of pathogenic virus such as
the modified vaccinia virus (MVA) and
adenovirus (Ad) are the most
clinically advanced viral vectors.
Image 1: Vaccinia virus and Adenovirus 
